Personalized Letter With Cancer Information Service Support or a Standard Reminder Letter in Women Scheduled for Colposcopy After an Abnormal Pap Test
Recruitment status was: Recruiting
RATIONALE: Receiving a reminder letter from their doctor with questions to ask the Cancer Information Service may be more effective than a standard reminder letter in helping patients who have had an abnormal Pap test keep their follow-up colposcopy appointment.
PURPOSE: This randomized clinical trial is studying a personalized letter with Cancer Information Service support to see how well it works compared with a standard reminder letter in women scheduled for colposcopy after an abnormal Pap test.
|Precancerous Condition||Other: informational intervention Other: questionnaire administration|
|Study Design:||Allocation: Randomized
Primary Purpose: Health Services Research
|Official Title:||Activating Collaborative CIS Support Via Targeted Provider Mailing|
- Patient satisfaction in the 2 interventions
- CIS experience of patients in arm II and the effect of the intervention on their follow-up colposcopy
- Attendance at a follow-up colposcopy appointment within 6 months of their Pap test
- Latency between the Pap test and the colposcopy appointment
- Number of CIS callers who provided the specific codes listed in the intervention letter
|Study Start Date:||October 2006|
|Estimated Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
- Compare the effect of a usual care mailing intervention vs a Cancer Information Service (CIS) support mailing intervention on the likelihood that women with an abnormal Pap test will keep their medical follow-up appointments and be satisfied with how they talk to their provider.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 intervention arms.
- Arm I (Usual-care mailing intervention): Patients receive a generic letter reminding them of their follow-up colposcopy appointment.
- Arm II (Cancer Information Service [CIS] support mailing intervention): Patients receive a targeted letter reminding them of their follow-up colposcopy appointment, asking them or someone they designate to call the CIS, and suggesting some questions to ask the CIS about colposcopies and Pap tests.
At their follow-up appointments, all patients undergo an exit interview to compare patient satisfaction between the 2 interventions. Patients in arm II also answer questions about their CIS experience, and if the intervention made their follow-up visit less difficult.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00873288
|United States, Illinois|
|Robert H. Lurie Comprehensive Cancer Center at Northwestern University||Recruiting|
|Chicago, Illinois, United States, 60611-3013|
|Contact: Clinical Trials Office - Robert H. Lurie Comprehensive Cancer 312-695-1301 firstname.lastname@example.org|
|Erie Family Health Center||Recruiting|
|Chicago, Illinois, United States, 60622|
|Contact: Contact Person Not Available email@example.com|
|Principal Investigator:||Bonnie Spring, PhD||Robert H. Lurie Cancer Center|